 | • レポートコード：QYR2104Z3044 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥565,500 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥848,250 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,131,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、免疫性血小板減少症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（静脈内免疫グロブリン、コルチコステロイド、トロンボポエチン受容体作動薬、その他）、用途別市場規模（病院・クリニック、専門センター、研究・学術機関、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・免疫性血小板減少症治療の市場動向 ・企業の競争状況、市場シェア ・免疫性血小板減少症治療の種類別市場規模（静脈内免疫グロブリン、コルチコステロイド、トロンボポエチン受容体作動薬、その他） ・免疫性血小板減少症治療の用途別市場規模（病院・クリニック、専門センター、研究・学術機関、その他） ・免疫性血小板減少症治療の北米市場規模2016-2027（アメリカ、カナダ） ・免疫性血小板減少症治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・免疫性血小板減少症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・免疫性血小板減少症治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・免疫性血小板減少症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（CSL、Amgen、F.Hoffmann-La Roche、Kyowa Hakko Kirin、Rigel Pharmaceuticals、Shionogi、Dova Pharmaceuticals、Novartis、Jiangsu Hengrui Pharmaceutical、Takeda、Ligand Pharmaceuticals） ・結論 |
Immune thrombocytopenia (ITP) is a bleeding disorder caused by thrombocytopenia not associated with a systemic disease. Typically, it is chronic in adults, but it is usually acute and self-limited in children. Spleen size is normal in the absence of another underlying condition.
The Immune Thrombocytopenia Treatment market is mostly driven by the factors such as rising prevalence of immune thrombocytopenia (ITP) worldwide, increased government effort to improve healthcare infrastructure, and increased focus on development of novel drugs and therapeutics.
Market Analysis and Insights: Global Immune Thrombocytopenia Treatment Market
The global Immune Thrombocytopenia Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Immune Thrombocytopenia Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Immune Thrombocytopenia Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Immune Thrombocytopenia Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Immune Thrombocytopenia Treatment market.
Global Immune Thrombocytopenia Treatment Scope and Market Size
Immune Thrombocytopenia Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Immune Thrombocytopenia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Intravenous Immunoglobulins
Corticosteroids
Thrombopoietin Receptor Agonists
Others
Segment by Application
Hospitals and Clinics
Specialty Centers
Research and Academic Institutes
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
CSL
Amgen
F.Hoffmann-La Roche
Kyowa Hakko Kirin
Rigel Pharmaceuticals
Shionogi
Dova Pharmaceuticals
Novartis
Jiangsu Hengrui Pharmaceutical
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Intravenous Immunoglobulins
1.2.3 Corticosteroids
1.2.4 Thrombopoietin Receptor Agonists
1.2.5 Others
1.3 Market by Application
1.3.1 Global Immune Thrombocytopenia Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals and Clinics
1.3.3 Specialty Centers
1.3.4 Research and Academic Institutes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Immune Thrombocytopenia Treatment Market Perspective (2016-2027)
2.2 Immune Thrombocytopenia Treatment Growth Trends by Regions
2.2.1 Immune Thrombocytopenia Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Immune Thrombocytopenia Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Immune Thrombocytopenia Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Immune Thrombocytopenia Treatment Industry Dynamic
2.3.1 Immune Thrombocytopenia Treatment Market Trends
2.3.2 Immune Thrombocytopenia Treatment Market Drivers
2.3.3 Immune Thrombocytopenia Treatment Market Challenges
2.3.4 Immune Thrombocytopenia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immune Thrombocytopenia Treatment Players by Revenue
3.1.1 Global Top Immune Thrombocytopenia Treatment Players by Revenue (2016-2021)
3.1.2 Global Immune Thrombocytopenia Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Immune Thrombocytopenia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Immune Thrombocytopenia Treatment Revenue
3.4 Global Immune Thrombocytopenia Treatment Market Concentration Ratio
3.4.1 Global Immune Thrombocytopenia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immune Thrombocytopenia Treatment Revenue in 2020
3.5 Immune Thrombocytopenia Treatment Key Players Head office and Area Served
3.6 Key Players Immune Thrombocytopenia Treatment Product Solution and Service
3.7 Date of Enter into Immune Thrombocytopenia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Immune Thrombocytopenia Treatment Breakdown Data by Type
4.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Type (2016-2021)
4.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Type (2022-2027)
5 Immune Thrombocytopenia Treatment Breakdown Data by Application
5.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Application (2016-2021)
5.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Immune Thrombocytopenia Treatment Market Size (2016-2027)
6.2 North America Immune Thrombocytopenia Treatment Market Size by Type
6.2.1 North America Immune Thrombocytopenia Treatment Market Size by Type (2016-2021)
6.2.2 North America Immune Thrombocytopenia Treatment Market Size by Type (2022-2027)
6.2.3 North America Immune Thrombocytopenia Treatment Market Size by Type (2016-2027)
6.3 North America Immune Thrombocytopenia Treatment Market Size by Application
6.3.1 North America Immune Thrombocytopenia Treatment Market Size by Application (2016-2021)
6.3.2 North America Immune Thrombocytopenia Treatment Market Size by Application (2022-2027)
6.3.3 North America Immune Thrombocytopenia Treatment Market Size by Application (2016-2027)
6.4 North America Immune Thrombocytopenia Treatment Market Size by Country
6.4.1 North America Immune Thrombocytopenia Treatment Market Size by Country (2016-2021)
6.4.2 North America Immune Thrombocytopenia Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Immune Thrombocytopenia Treatment Market Size (2016-2027)
7.2 Europe Immune Thrombocytopenia Treatment Market Size by Type
7.2.1 Europe Immune Thrombocytopenia Treatment Market Size by Type (2016-2021)
7.2.2 Europe Immune Thrombocytopenia Treatment Market Size by Type (2022-2027)
7.2.3 Europe Immune Thrombocytopenia Treatment Market Size by Type (2016-2027)
7.3 Europe Immune Thrombocytopenia Treatment Market Size by Application
7.3.1 Europe Immune Thrombocytopenia Treatment Market Size by Application (2016-2021)
7.3.2 Europe Immune Thrombocytopenia Treatment Market Size by Application (2022-2027)
7.3.3 Europe Immune Thrombocytopenia Treatment Market Size by Application (2016-2027)
7.4 Europe Immune Thrombocytopenia Treatment Market Size by Country
7.4.1 Europe Immune Thrombocytopenia Treatment Market Size by Country (2016-2021)
7.4.2 Europe Immune Thrombocytopenia Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size (2016-2027)
8.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type
8.2.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application
8.3.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region
8.4.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Immune Thrombocytopenia Treatment Market Size (2016-2027)
9.2 Latin America Immune Thrombocytopenia Treatment Market Size by Type
9.2.1 Latin America Immune Thrombocytopenia Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Immune Thrombocytopenia Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Immune Thrombocytopenia Treatment Market Size by Type (2016-2027)
9.3 Latin America Immune Thrombocytopenia Treatment Market Size by Application
9.3.1 Latin America Immune Thrombocytopenia Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Immune Thrombocytopenia Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Immune Thrombocytopenia Treatment Market Size by Application (2016-2027)
9.4 Latin America Immune Thrombocytopenia Treatment Market Size by Country
9.4.1 Latin America Immune Thrombocytopenia Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Immune Thrombocytopenia Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size (2016-2027)
10.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type
10.2.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application
10.3.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country
10.4.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 CSL
11.1.1 CSL Company Details
11.1.2 CSL Business Overview
11.1.3 CSL Immune Thrombocytopenia Treatment Introduction
11.1.4 CSL Revenue in Immune Thrombocytopenia Treatment Business (2016-2021)
11.1.5 CSL Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Immune Thrombocytopenia Treatment Introduction
11.2.4 Amgen Revenue in Immune Thrombocytopenia Treatment Business (2016-2021)
11.2.5 Amgen Recent Development
11.3 F.Hoffmann-La Roche
11.3.1 F.Hoffmann-La Roche Company Details
11.3.2 F.Hoffmann-La Roche Business Overview
11.3.3 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Introduction
11.3.4 F.Hoffmann-La Roche Revenue in Immune Thrombocytopenia Treatment Business (2016-2021)
11.3.5 F.Hoffmann-La Roche Recent Development
11.4 Kyowa Hakko Kirin
11.4.1 Kyowa Hakko Kirin Company Details
11.4.2 Kyowa Hakko Kirin Business Overview
11.4.3 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Introduction
11.4.4 Kyowa Hakko Kirin Revenue in Immune Thrombocytopenia Treatment Business (2016-2021)
11.4.5 Kyowa Hakko Kirin Recent Development
11.5 Rigel Pharmaceuticals
11.5.1 Rigel Pharmaceuticals Company Details
11.5.2 Rigel Pharmaceuticals Business Overview
11.5.3 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
11.5.4 Rigel Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2016-2021)
11.5.5 Rigel Pharmaceuticals Recent Development
11.6 Shionogi
11.6.1 Shionogi Company Details
11.6.2 Shionogi Business Overview
11.6.3 Shionogi Immune Thrombocytopenia Treatment Introduction
11.6.4 Shionogi Revenue in Immune Thrombocytopenia Treatment Business (2016-2021)
11.6.5 Shionogi Recent Development
11.7 Dova Pharmaceuticals
11.7.1 Dova Pharmaceuticals Company Details
11.7.2 Dova Pharmaceuticals Business Overview
11.7.3 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
11.7.4 Dova Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2016-2021)
11.7.5 Dova Pharmaceuticals Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Immune Thrombocytopenia Treatment Introduction
11.8.4 Novartis Revenue in Immune Thrombocytopenia Treatment Business (2016-2021)
11.8.5 Novartis Recent Development
11.9 Jiangsu Hengrui Pharmaceutical
11.9.1 Jiangsu Hengrui Pharmaceutical Company Details
11.9.2 Jiangsu Hengrui Pharmaceutical Business Overview
11.9.3 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Introduction
11.9.4 Jiangsu Hengrui Pharmaceutical Revenue in Immune Thrombocytopenia Treatment Business (2016-2021)
11.9.5 Jiangsu Hengrui Pharmaceutical Recent Development
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Immune Thrombocytopenia Treatment Introduction
11.10.4 Takeda Revenue in Immune Thrombocytopenia Treatment Business (2016-2021)
11.10.5 Takeda Recent Development
11.11 Ligand Pharmaceuticals
11.11.1 Ligand Pharmaceuticals Company Details
11.11.2 Ligand Pharmaceuticals Business Overview
11.11.3 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Introduction
11.11.4 Ligand Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2016-2021)
11.11.5 Ligand Pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Immune Thrombocytopenia Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Intravenous Immunoglobulins
Table 3. Key Players of Corticosteroids
Table 4. Key Players of Thrombopoietin Receptor Agonists
Table 5. Key Players of Others
Table 6. Global Immune Thrombocytopenia Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Immune Thrombocytopenia Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Immune Thrombocytopenia Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Immune Thrombocytopenia Treatment Market Share by Regions (2016-2021)
Table 10. Global Immune Thrombocytopenia Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Immune Thrombocytopenia Treatment Market Share by Regions (2022-2027)
Table 12. Immune Thrombocytopenia Treatment Market Trends
Table 13. Immune Thrombocytopenia Treatment Market Drivers
Table 14. Immune Thrombocytopenia Treatment Market Challenges
Table 15. Immune Thrombocytopenia Treatment Market Restraints
Table 16. Global Immune Thrombocytopenia Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Immune Thrombocytopenia Treatment Market Share by Players (2016-2021)
Table 18. Global Top Immune Thrombocytopenia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immune Thrombocytopenia Treatment as of 2020)
Table 19. Ranking of Global Top Immune Thrombocytopenia Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Immune Thrombocytopenia Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Immune Thrombocytopenia Treatment Product Solution and Service
Table 23. Date of Enter into Immune Thrombocytopenia Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Immune Thrombocytopenia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Immune Thrombocytopenia Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Immune Thrombocytopenia Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Immune Thrombocytopenia Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Immune Thrombocytopenia Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Immune Thrombocytopenia Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Immune Thrombocytopenia Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Immune Thrombocytopenia Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Immune Thrombocytopenia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Immune Thrombocytopenia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Immune Thrombocytopenia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Immune Thrombocytopenia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Immune Thrombocytopenia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Immune Thrombocytopenia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Immune Thrombocytopenia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Immune Thrombocytopenia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Immune Thrombocytopenia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Immune Thrombocytopenia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Immune Thrombocytopenia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Immune Thrombocytopenia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Immune Thrombocytopenia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Immune Thrombocytopenia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Immune Thrombocytopenia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Immune Thrombocytopenia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Immune Thrombocytopenia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Immune Thrombocytopenia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. CSL Company Details
Table 64. CSL Business Overview
Table 65. CSL Immune Thrombocytopenia Treatment Product
Table 66. CSL Revenue in Immune Thrombocytopenia Treatment Business (2016-2021) & (US$ Million)
Table 67. CSL Recent Development
Table 68. Amgen Company Details
Table 69. Amgen Business Overview
Table 70. Amgen Immune Thrombocytopenia Treatment Product
Table 71. Amgen Revenue in Immune Thrombocytopenia Treatment Business (2016-2021) & (US$ Million)
Table 72. Amgen Recent Development
Table 73. F.Hoffmann-La Roche Company Details
Table 74. F.Hoffmann-La Roche Business Overview
Table 75. F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Product
Table 76. F.Hoffmann-La Roche Revenue in Immune Thrombocytopenia Treatment Business (2016-2021) & (US$ Million)
Table 77. F.Hoffmann-La Roche Recent Development
Table 78. Kyowa Hakko Kirin Company Details
Table 79. Kyowa Hakko Kirin Business Overview
Table 80. Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Product
Table 81. Kyowa Hakko Kirin Revenue in Immune Thrombocytopenia Treatment Business (2016-2021) & (US$ Million)
Table 82. Kyowa Hakko Kirin Recent Development
Table 83. Rigel Pharmaceuticals Company Details
Table 84. Rigel Pharmaceuticals Business Overview
Table 85. Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Product
Table 86. Rigel Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2016-2021) & (US$ Million)
Table 87. Rigel Pharmaceuticals Recent Development
Table 88. Shionogi Company Details
Table 89. Shionogi Business Overview
Table 90. Shionogi Immune Thrombocytopenia Treatment Product
Table 91. Shionogi Revenue in Immune Thrombocytopenia Treatment Business (2016-2021) & (US$ Million)
Table 92. Shionogi Recent Development
Table 93. Dova Pharmaceuticals Company Details
Table 94. Dova Pharmaceuticals Business Overview
Table 95. Dova Pharmaceuticals Immune Thrombocytopenia Treatment Product
Table 96. Dova Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2016-2021) & (US$ Million)
Table 97. Dova Pharmaceuticals Recent Development
Table 98. Novartis Company Details
Table 99. Novartis Business Overview
Table 100. Novartis Revenue in Immune Thrombocytopenia Treatment Business (2016-2021) & (US$ Million)
Table 101. Novartis Recent Development
Table 102. Jiangsu Hengrui Pharmaceutical Company Details
Table 103. Jiangsu Hengrui Pharmaceutical Business Overview
Table 104. Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Product
Table 105. Jiangsu Hengrui Pharmaceutical Revenue in Immune Thrombocytopenia Treatment Business (2016-2021) & (US$ Million)
Table 106. Jiangsu Hengrui Pharmaceutical Recent Development
Table 107. Takeda Company Details
Table 108. Takeda Business Overview
Table 109. Takeda Immune Thrombocytopenia Treatment Product
Table 110. Takeda Revenue in Immune Thrombocytopenia Treatment Business (2016-2021) & (US$ Million)
Table 111. Takeda Recent Development
Table 112. Ligand Pharmaceuticals Company Details
Table 113. Ligand Pharmaceuticals Business Overview
Table 114. Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Product
Table 115. Ligand Pharmaceuticals Revenue in Immune Thrombocytopenia Treatment Business (2016-2021) & (US$ Million)
Table 116. Ligand Pharmaceuticals Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Immune Thrombocytopenia Treatment Market Share by Type: 2020 VS 2027
Figure 2. Intravenous Immunoglobulins Features
Figure 3. Corticosteroids Features
Figure 4. Thrombopoietin Receptor Agonists Features
Figure 5. Others Features
Figure 6. Global Immune Thrombocytopenia Treatment Market Share by Application: 2020 VS 2027
Figure 7. Hospitals and Clinics Case Studies
Figure 8. Specialty Centers Case Studies
Figure 9. Research and Academic Institutes Case Studies
Figure 10. Others Case Studies
Figure 11. Immune Thrombocytopenia Treatment Report Years Considered
Figure 12. Global Immune Thrombocytopenia Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Immune Thrombocytopenia Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Immune Thrombocytopenia Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Immune Thrombocytopenia Treatment Market Share by Regions (2022-2027)
Figure 16. Global Immune Thrombocytopenia Treatment Market Share by Players in 2020
Figure 17. Global Top Immune Thrombocytopenia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immune Thrombocytopenia Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Immune Thrombocytopenia Treatment Revenue in 2020
Figure 19. Global Immune Thrombocytopenia Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Immune Thrombocytopenia Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Immune Thrombocytopenia Treatment Market Share by Type (2016-2027)
Figure 23. North America Immune Thrombocytopenia Treatment Market Share by Application (2016-2027)
Figure 24. North America Immune Thrombocytopenia Treatment Market Share by Country (2016-2027)
Figure 25. United States Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Immune Thrombocytopenia Treatment Market Share by Type (2016-2027)
Figure 29. Europe Immune Thrombocytopenia Treatment Market Share by Application (2016-2027)
Figure 30. Europe Immune Thrombocytopenia Treatment Market Share by Country (2016-2027)
Figure 31. Germany Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Immune Thrombocytopenia Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Immune Thrombocytopenia Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Immune Thrombocytopenia Treatment Market Share by Region (2016-2027)
Figure 41. China Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Immune Thrombocytopenia Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Immune Thrombocytopenia Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Immune Thrombocytopenia Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Immune Thrombocytopenia Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Immune Thrombocytopenia Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Immune Thrombocytopenia Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Immune Thrombocytopenia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. CSL Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2016-2021)
Figure 61. Amgen Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2016-2021)
Figure 62. F.Hoffmann-La Roche Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2016-2021)
Figure 63. Kyowa Hakko Kirin Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2016-2021)
Figure 64. Rigel Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2016-2021)
Figure 65. Shionogi Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2016-2021)
Figure 66. Dova Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2016-2021)
Figure 67. Novartis Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2016-2021)
Figure 68. Jiangsu Hengrui Pharmaceutical Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2016-2021)
Figure 69. Takeda Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2016-2021)
Figure 70. Ligand Pharmaceuticals Revenue Growth Rate in Immune Thrombocytopenia Treatment Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
世界の化学療法誘発性血小板減少症治療市場規模・現状・予測（2021年-2027年） Cancer is a major chronic disease, which can be managed and treated by chemotherapy, radiation therapy, immunotherapy, hormone therapy, stem cell transplant, targeted therapy, and other therapies. Cancer can be treated by using one therapy or by using combination of therapies based on the stage, typ…- 世界の免疫性炎症性疾患治療市場規模・現状・予測（2021年-2027年） Immune-Mediated Inflammatory Diseases Treatment is any of a group of conditions or diseases that lack a definitive etiology, but which are characterized by common inflammatory pathways leading to inflammation, and which may result from, or be triggered by, a dysregulation of the normal immune respon…
- 世界の血小板減少症管理市場規模・現状・予測（2021年-2027年） Thrombocytopenia is deficiency of platelets in the blood vessels, an auto immune hematological bleeding disorder. Due to high response rates from patients, increasing awareness and disposable income, the global thrombocytopenia management market is gradually increasing. Market Analysis and Insights:…
- 世界の血小板減少症管理市場 2021：企業別、地域別、種類・用途別 The Thrombocytopenia Management market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…
- 世界の末梢神経障害治療市場規模・現状・予測（2021年-2027年） Peripheral neuropathy is a set of symptoms caused by any damage to the nerves that are away from the brain and spinal cord. Peripheral neuropathy is not a single, homogenous disease, but it is a mix of different clinical presentations, natural histories, and pathology. Market Analysis and Insights: …